Treatment for Grass Allergy Reaction
For grass pollen allergy reactions, implement a three-tiered approach: environmental avoidance measures as first-line, pharmacologic symptom control with antihistamines and nasal corticosteroids as needed, and allergen immunotherapy (either subcutaneous or sublingual) for patients with moderate-to-severe symptoms inadequately controlled by medications.
Environmental Control Measures (First-Line)
Pollen avoidance is foundational and should be aggressively implemented 1:
- Keep windows and doors closed during grass pollen season (late spring to early summer in temperate North America)
- Close outdoor vents when using air conditioning in home and vehicle
- Limit outdoor activities when pollen counts are high, particularly on sunny, windy days with low humidity
- Plan outdoor activities for early morning or late evening when pollen concentrations are lower
- Shower or bathe immediately after outdoor exposure to remove pollen from skin and hair
- Wash pets after outdoor exposure, as they serve as pollen vectors
- Consider wearing a facemask during unavoidable outdoor activities for highly sensitive patients 1
These measures reduce indoor pollen exposure and symptom "priming" (progressive nasal inflammation that lowers the threshold for allergic reactions) 1.
Pharmacologic Treatment (Symptomatic Control)
While the provided evidence focuses primarily on immunotherapy and environmental control, standard practice includes:
- Oral antihistamines for sneezing, itching, and rhinorrhea
- Intranasal corticosteroids for nasal congestion and inflammation
- Ocular antihistamines for conjunctival symptoms
- Rescue medications should be used as needed during pollen exposure
Allergen Immunotherapy (Disease-Modifying Treatment)
For patients aged 5 years and older with moderate-to-severe symptoms despite environmental control and medications, allergen immunotherapy provides the only disease-modifying treatment with lasting benefits 2.
Two Equally Effective Options:
Subcutaneous Immunotherapy (SCIT):
- Administered as injections under the skin
- Recent evidence shows unprecedented efficacy of up to 40% reduction in combined symptom and medication scores with optimized grass pollen SCIT using only 6 pre-seasonal injections 3
- Cluster protocols can achieve maintenance dosing within 1 week, with significant symptom reduction (P=0.005) and medication use reduction (P=0.002) 4
- Requires in-office administration with observation period
Sublingual Immunotherapy (SLIT):
- Administered as tablets or drops under the tongue at home
- 5-grass pollen tablet showed 65.5% reduction in rhinoconjunctivitis scores over 2 years (P<0.001) with 83.8% to 42.7% reduction in patients requiring symptomatic medication 5
- Standardized grass allergen tablet (75,000 SQ-T) demonstrated 30-36% reduction in symptom scores and 38-46% reduction in medication scores over multiple seasons 6, 7
- More convenient but requires daily adherence
Key Advantages of Immunotherapy:
- Lasting benefits persist after treatment discontinuation (unlike symptomatic medications) 2
- Prevents development of new allergies and asthma 2
- Reduces asthma symptoms in patients with concurrent asthma 2
- Effective across different clinical profiles: monoallergy vs. polyallergy, with or without asthma 5
Safety Profile:
Both SCIT and SLIT are well-tolerated. Local reactions (oral itching, edema, throat irritation) occur in approximately 15% of patients but are typically mild and transient 5, 7. Systemic reactions with SCIT are rare (0.8% of injections) and mild 4. No anaphylaxis or epinephrine use was documented in large real-world studies 5.
Treatment Algorithm:
- All patients: Implement aggressive environmental avoidance
- Mild symptoms: Environmental control + as-needed antihistamines
- Moderate-to-severe symptoms OR inadequate control with medications: Add immunotherapy (SCIT or SLIT based on patient preference regarding convenience vs. office visits)
- Polyallergic patients: Immunotherapy remains effective and can be combined with treatment for other allergens 5
Common Pitfall to Avoid:
Do not delay immunotherapy in patients with persistent moderate-to-severe symptoms. Immunotherapy is not just for "treatment failures"—it should be offered early to patients preferring disease modification over chronic medication use 2.